Lakewood-Amedex Debuts on Nasdaq, Targeting Diabetic Foot Ulcer Market
Event summary
- Lakewood-Amedex Biotherapeutics began trading on Nasdaq under ticker 'LABT' April 23, 2026
- Company plans to initiate Phase 2a clinical trial for lead product Nu-3 in infected diabetic foot ulcers (iDFU)
- Nu-3 targets a $40M US patient population with high infection and antibiotic resistance risks
- Bisphosphocin® class antimicrobials aim to combat resistant strains like MRSA and VRE
The big picture
Lakewood-Amedex's Nasdaq debut comes as antibiotic resistance continues to threaten diabetic wound care, a $14B market segment. The company joins peers like Destum and Cardeas Pharma in targeting infected diabetic foot ulcers with novel mechanisms, but faces pressure to demonstrate superior efficacy against established treatments. Success hinges on proving Nu-3's ability to penetrate biofilms while maintaining safety in topical applications.
What we're watching
- Clinical Progress
- How quickly Lakewood-Amedex advances Nu-3 through Phase 2 trials and whether initial results validate its broad-spectrum claims against resistant strains.
- Market Positioning
- Whether the company can differentiate itself in the crowded antimicrobial space by leveraging its unique mechanism of action against biofilms.
- Capital Efficiency
- The pace at which Lakewood-Amedex converts its Nasdaq listing into accelerated development timelines without excessive dilution.
Our editorial coverage:
Related topics